Inspire Medical Systems (NYSE:INSP) Price Target Raised to $130.00

Inspire Medical Systems (NYSE:INSP) had its target price boosted by Mizuho from $110.00 to $130.00 in a report issued on Wednesday, Marketbeat.com reports. They currently have an outperform rating on the stock.

Several other research firms also recently issued reports on INSP. Zacks Research upgraded Inspire Medical Systems from a “strong sell” rating to a “hold” rating in a report on Monday, October 27th. Robert W. Baird lifted their target price on shares of Inspire Medical Systems from $125.00 to $180.00 and gave the stock an “outperform” rating in a research report on Thursday, December 4th. Evercore ISI cut their price target on shares of Inspire Medical Systems from $150.00 to $125.00 and set an “outperform” rating on the stock in a report on Tuesday, October 7th. UBS Group set a $89.00 price objective on shares of Inspire Medical Systems and gave the stock a “neutral” rating in a research note on Monday, September 22nd. Finally, Stifel Nicolaus set a $110.00 price objective on shares of Inspire Medical Systems and gave the stock a “buy” rating in a research report on Monday, November 24th. Eleven equities research analysts have rated the stock with a Buy rating, seven have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $138.88.

Inspire Medical Systems Stock Performance

Shares of NYSE:INSP opened at $96.39 on Wednesday. The company has a market capitalization of $2.80 billion, a PE ratio of 65.57, a price-to-earnings-growth ratio of 10.98 and a beta of 0.70. The stock has a fifty day moving average of $99.58 and a 200-day moving average of $103.72. Inspire Medical Systems has a one year low of $70.77 and a one year high of $216.01.

Inspire Medical Systems (NYSE:INSP) last announced its earnings results on Monday, November 3rd. The company reported $0.38 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.15) by $0.53. Inspire Medical Systems had a return on equity of 9.41% and a net margin of 5.05%.The company had revenue of $224.50 million for the quarter, compared to analyst estimates of $220.39 million. During the same period in the previous year, the firm earned $0.60 earnings per share. Inspire Medical Systems’s revenue for the quarter was up 10.5% compared to the same quarter last year. As a group, research analysts forecast that Inspire Medical Systems will post 2.16 EPS for the current fiscal year.

Insider Transactions at Inspire Medical Systems

In other Inspire Medical Systems news, Director Shawn Mccormick sold 2,000 shares of Inspire Medical Systems stock in a transaction on Friday, November 28th. The shares were sold at an average price of $127.48, for a total transaction of $254,960.00. Following the completion of the sale, the director owned 26,046 shares of the company’s stock, valued at $3,320,344.08. This trade represents a 7.13% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. 4.10% of the stock is currently owned by insiders.

Institutional Trading of Inspire Medical Systems

A number of institutional investors have recently added to or reduced their stakes in INSP. Manning & Napier Advisors LLC acquired a new position in shares of Inspire Medical Systems during the 3rd quarter worth $32,000. Quarry LP boosted its holdings in Inspire Medical Systems by 2,127.3% in the first quarter. Quarry LP now owns 245 shares of the company’s stock worth $39,000 after purchasing an additional 234 shares in the last quarter. Banque Transatlantique SA bought a new stake in Inspire Medical Systems in the first quarter worth $46,000. Larson Financial Group LLC increased its position in Inspire Medical Systems by 21,266.7% during the third quarter. Larson Financial Group LLC now owns 641 shares of the company’s stock worth $48,000 after buying an additional 638 shares during the last quarter. Finally, Pilgrim Partners Asia Pte Ltd bought a new position in Inspire Medical Systems during the third quarter valued at about $49,000. 94.91% of the stock is currently owned by institutional investors and hedge funds.

Inspire Medical Systems News Summary

Here are the key news stories impacting Inspire Medical Systems this week:

• Positive Sentiment: Several brokerages have signaled confidence by raising targets or keeping bullish ratings — Mizuho lifted its target to $130 and maintained Outperform, and JPMorgan raised its target to $118; Bank of America and Robert W. Baird issued buy/reaffirmations, supporting upside expectations. Mizuho Raises INSP Price Target JPMorgan Boosts INSP PT Baird Reaffirms Buy
• Neutral Sentiment: Market commentary is revisiting valuation after a sharp share slide — useful for investors assessing risk/reward but dependent on how reimbursement and legal issues evolve. Revisiting Valuation
• Negative Sentiment: Numerous law firms have filed investor alerts and securities class-action notices tied to a large share drop (cited ~$42.04) alleging concealed Medicare billing software failures and inventory problems — multiple firms are soliciting lead-plaintiff roles ahead of a Jan. 5, 2026 deadline. This raises litigation risk, potential costs and distraction for management. Rosen Law Firm Notice PR Newswire Lawsuit Notice
• Negative Sentiment: Coverage ties the share decline to a Medicare reimbursement/coding change and alleged operational issues; articles explain a sharp drop (reported 23–30% moves) and cite the Medicare policy shift as the proximate catalyst — a fundamental reimbursement risk that could materially affect revenue if not resolved or mitigated. Why INSP Is Down After Medicare Coding Shift AAII Explainer

About Inspire Medical Systems

Inspire Medical Systems, Inc is a medical technology company specializing in implantable neurostimulation devices for the treatment of obstructive sleep apnea (OSA). The company’s flagship offering, the Inspire® system, delivers targeted stimulation of the hypoglossal nerve to maintain airway patency during sleep, providing an alternative therapy for patients who are intolerant of or inadequately managed by continuous positive airway pressure (CPAP) devices.

The Inspire system comprises an implantable pulse generator, a sensing lead that monitors breathing patterns, and a stimulation lead that activates the hypoglossal nerve.